OPEN END TURBO OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 12:53:22 24/06/2024 BST | ||
| 15.9 EUR / 16.2 EUR | +0.25% |
|
| Current month | -6.04% | ||
| 1 month | -13.27% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24/06/24 | 15.96 | -0.31% |
| 21/06/24 | 16.01 | +0.13% |
| 20/06/24 | 15.99 | -1.84% |
| 19/06/24 | 16.29 | +0.18% |
| 18/06/24 | 16.26 | +4.03% |
Delayed Quote Börse Stuttgart
Last update June 24, 2024 at 11:59 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JK1XP6 |
| ISIN | DE000JK1XP65 |
| Date issued | 16/01/2024 |
| Strike | 640.9 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 19.31 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 23.43 € |
|---|---|
| Lowest since issue | 14.27 € |
| Spread | 0.3 € |
| Spread % | 1.84% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
468.7
USD
Average target price
463.4
USD
Spread / Average Target
-1.13%
- Stock Market
- Certificates
- Certificat
